NVS Novartis AG
- 97.440
- -1.620-1.64%
- 97.440
- 0.0000.00%
Novartis AG News
Novartis AG | S-8 POS: S-8 POS
Novartis AG | 6-K: Annual Report 2023 and Novartis in Society - Integrated Report 2023
Novartis AG | 6-K: Novartis Scemblix® Shows Superior Major Molecular Response (Mmr) Rates Vs. Standard-of-Care Tkis in Phase Iii Trial for Newly Diagnosed Patients with Chronic Myeloid Leukemia
Novartis AG | 6-K: Novartis Investigational Iptacopan Phase Iii Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3g)
Novartis AG | 6-K: Novartis Receives Fda Approval for Fabhalta® (Iptacopan)
Novartis AG | 6-K: Novartis Upgrades Mid-Term Sales Growth Guidance, Showcases Its Differentiated Innovative Medicines Strategy and Robust Pipeline at R&d Day
Novartis AG | 6-K: Report of Foreign Private Issuer
Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Novartis AG | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Novartis AG | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
Novartis AG | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Novartis AG | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Novartis AG | S-8 POS: S-8 POS
Novartis AG | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Novartis AG | S-8 POS: S-8 POS
Novartis AG | F-6 POS: Post-effective amendment to a F-6EF registration
Novartis AG | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
